23948sdkhjf

Fakta om udbudet

EU-nr
2018/S 203-463274
Offentliggjort
20.10.2018
Udbudstype
Tildeling af kontrakt uden forudgående offentliggørelse

Udbyder

Kungliga Tekniska högskolan

Vindere

(20.10.2018)
Icosagen Cell Factory OÜ
61713 Õssu

License for the QMCF Technology


Kungliga Tekniska högskolan

Voluntary ex ante transparency notice

Services

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority/entity

I.1) Name and addresses
Kungliga Tekniska högskolan
202100-3054
Teknikringen 30
Stockholm
10691
Sweden
Contact person: Kicki Holmberg
E-mail: hoki@kth.se
NUTS code: SE11

Internet address(es):

Main address: http://www.kth.se

I.4) Type of the contracting authority
National or federal agency/office
I.5) Main activity
Education

Section II: Object

II.1) Scope of the procurement
II.1.1) Title:

License for the QMCF Technology

Reference number: C-2018-1662
II.1.2) Main CPV code
71900000
II.1.3) Type of contract
Services
II.1.4) Short description:

The Human Secretome project within the Wallenberg Center for Protein Research at the Royal Institute of Technology (KTH) has set up at high-throughput protein production pipeline to be able to produce a large number of recombinant proteins in CHO cells yearly. The expression system that we use is based on the so called QMCF Technology. In order to continue our work we must have a licence to use the QMCF Technology.

II.1.6) Information about lots
This contract is divided into lots: no
II.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: 100 000.00 EUR
II.2) Description
II.2.1) Title:
II.2.2) Additional CPV code(s)
II.2.3) Place of performance
NUTS code: SE110
II.2.4) Description of the procurement:

The Human Secretome project within the Wallenberg Center for Protein Research at the Royal Institute of Technology (KTH) has since the start of the project (2013) been using a technology called the QMCF Technology (Patent number: EP1851319). It is an expression system that uses specific mammalian cells (QMCF cell lines) and vectors (QMCF plasmids) for production of recombinant proteins. At KTH we use this technology to produce a large number of recombinant proteins in Chinese Hamster Ovary (CHO) cells yearly. In order to continue our work we must have a licence to use the QMCF Technology. Icosagen Cell Factory OÜ is the only company that can provide the needed license.

II.2.5) Award criteria
II.2.11) Information about options
Options: no
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14) Additional information

Section IV: Procedure

IV.1) Description
IV.1.1) Type of procedure
Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below
  • The procurement falls outside the scope of application of the directive
Explanation:

The Human Secretome project within the Wallenberg Center for Protein Research at the Royal Institute of Technology (KTH) has since the start of the project (2013) been using a technology called the QMCF Technology (Patent number: EP1851319) developed by the Estonian company Icosagen Cell Factory OÜ. It is an expression system that uses specific mammalian cells (QMCF cell lines) and vectors (QMCF plasmids) for production of recombinant proteins and has been chosen after extensive testing of different expression systems. By using this technology we are able to produce a large number of recombinant proteins in Chinese Hamster Ovary (CHO) cells yearly. Today we have generated over 3,000 expression vectors that all are designed to work exclusively in Icosagen QMCF cells. In order to continue our work we must have a licence to use the QMCF Technology. The Royal Institute of technology (KTH) must therefore pay a license fee to Icosagen Cell Factory OÜ (25,000 EUR per year). Icosagen is the only company that can provide the needed license.

IV.1.3) Information about framework agreement
IV.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure

Section V: Award of contract/concession

V.2) Award of contract/concession
V.2.1) Date of contract award decision:
16/10/2018
V.2.2) Information about tenders
The contract has been awarded to a group of economic operators: no
V.2.3) Name and address of the contractor/concessionaire
Icosagen Cell Factory OÜ
11107818
Õssu
61713
Estonia
Telephone: +372 7377055
NUTS code: EE
The contractor/concessionaire will be an SME: yes
V.2.4) Information on value of the contract/lot/concession (excluding VAT)
Initial estimated total value of the contract/lot/concession: 100 000.00 EUR
Total value of the contract/lot/concession: 100 000.00 EUR
V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information:
VI.4) Procedures for review
VI.4.1) Review body
Förvaltningsrätten i Stockholm
Stockholm
Sweden
VI.4.2) Body responsible for mediation procedures
VI.4.3) Review procedure
VI.4.4) Service from which information about the review procedure may be obtained
VI.5) Date of dispatch of this notice:
17/10/2018

Send til en kollega

0.163